These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 17971363

  • 21. [Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].
    Frutos MA, Martín Gómez A, de Ramón E, Camps MT, Valera A, García I, Fernández Nebro A.
    Nefrologia; 2007; 27(1):12-22. PubMed ID: 17402875
    [Abstract] [Full Text] [Related]

  • 22. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 23. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 24. Mizoribine for the treatment of lupus nephritis in children and adolescents.
    Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, Waga S.
    Clin Nephrol; 2004 Dec; 62(6):412-7. PubMed ID: 15630899
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
    Illei GG, Yarboro CH, Kuroiwa T, Schlimgen R, Austin HA, Tisdale JF, Chitkara P, Fleisher T, Klippel JH, Balow JE, Boumpas DT.
    Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
    [Abstract] [Full Text] [Related]

  • 29. Cyclosporine treatment of lupus membranous nephropathy.
    Radhakrishnan J, Kunis CL, D'Agati V, Appel GB.
    Clin Nephrol; 1994 Sep; 42(3):147-54. PubMed ID: 7994932
    [Abstract] [Full Text] [Related]

  • 30. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.
    Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group.
    Arthritis Rheum; 2003 Mar; 48(3):719-27. PubMed ID: 12632425
    [Abstract] [Full Text] [Related]

  • 31. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 32. [Evaluation of serum C3 and CH50 levels as markers of disease-activity and indicators of efficacy of treatment of lupus nephritis in childhood].
    Ibe M, Kuriyama T, Mori M, Mitsuda T, Aihara Y, Yokota S.
    Ryumachi; 1994 Aug; 34(4):715-24. PubMed ID: 7974022
    [Abstract] [Full Text] [Related]

  • 33. An open study of B lymphocyte depletion in systemic lupus erythematosus.
    Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA.
    Arthritis Rheum; 2002 Oct; 46(10):2673-7. PubMed ID: 12384926
    [Abstract] [Full Text] [Related]

  • 34. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.
    J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
    [Abstract] [Full Text] [Related]

  • 35. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 37. [Intermittent intravenous administration of cyclophosphamide in patients with lupus nephritis].
    Morović-Vergles J, Galesić K, Dancuo I, Vergles D.
    Acta Med Croatica; 2004 May; 58(1):13-7. PubMed ID: 15125388
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.
    Ogawa H, Kameda H, Amano K, Takeuchi T.
    Lupus; 2010 Feb; 19(2):162-9. PubMed ID: 19952069
    [Abstract] [Full Text] [Related]

  • 39. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study.
    Fei Y, Wu Q, Zhang W, Chen H, Hou Y, Xu D, Li M, Zhang X, Zhao Y, Zeng X, Zhang F.
    Clin Exp Rheumatol; 2013 Feb; 31(1):62-8. PubMed ID: 22935463
    [Abstract] [Full Text] [Related]

  • 40. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.